Atlas Trials

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Clinical trial NCT03907527 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03907527
Sponsor
Precigen, Inc
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRefractory Fallopian Tube CarcinomaRefractory Ovarian CarcinomaRefractory Primary Peritoneal CarcinomaStage III Fallopian Tube Cancer AJCC V8Stage III Ovarian Cancer AJCC V8Stage III Primary Peritoneal Cancer AJCC V8
Start date
2019-04-30
Primary completion
2024-12-15
Enrollment
71

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.